Fast Five Quiz: Treatment in Relapsed Multiple Sclerosis

Kerstin Hellwig, MD; Christopher Luzzio, MD


November 22, 2022

In the early stage of the pandemic, there was a concern that patients on certain DMTs who developed COVID-19 would face a high risk for MS relapse, but data have shown that with consistent administration of DMTs, the risk for MS relapse with COVID is minimal. Globally, a number of registries have attempted to determine what effect COVID has on MS and vice versa, including the COViMS Registry in North America, a UK registry, a Swedish registry, and an Austrian registry. Although some studies suggest that patients with MS who develop COVID may face increased morbidity and mortality, the data are conflicting. A 2022 systematic review by Smith and colleagues showed no increase in the risk for COVID-19 infection among patients with MS on DMT.

Learn more about COVID-19 risk in patients with MS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.